Ali Myzoon, MacIsaac Rachael, Quinn Terence J, Bath Philip M, Veenstra David L, Xu Yaping, Brady Marian C, Patel Anita, Lees Kennedy R
Institutes of Cardiovascular and Medical Sciences, Queen Elizabeth University Hospital, Glasgow, UK.
Institutes of Cardiovascular and Medical Sciences, Glasgow Royal Infirmary, Glasgow, UK.
Eur Stroke J. 2017 Mar;2(1):70-76. doi: 10.1177/2396987316683780. Epub 2017 Mar 1.
Health utilities (HU) assign preference weights to specific health states and are required for cost-effectiveness analyses. Existing HU for stroke inadequately reflect the spectrum of post-stroke disability. Using international stroke trial data, we calculated HU stratified by disability to improve precision in future cost-effectiveness analyses.
We used European Quality of Life Score (EQ-5D-3L) data from the Virtual International Stroke Trials Archive (VISTA) to calculate HU, stratified by modified Rankin Scale scores (mRS) at 3 months. We applied published value sets to generate HU, and validated these using ordinary least squares regression, adjusting for age and baseline National Institutes of Health Stroke Scale (NIHSS) scores.
We included 3858 patients with acute ischemic stroke in our analysis (mean age: 67.5 ± 12.5, baseline NIHSS: 12 ± 5). We derived HU using value sets from 13 countries and observed significant international variation in HU distributions (Wilcoxon signed-rank test < 0.0001, compared with UK values). For mRS = 0, mean HU ranged from 0.88 to 0.95; for mRS = 5, mean HU ranged from -0.48 to 0.22. OLS regression generated comparable HU (for mRS = 0, HU ranged from 0.9 to 0.95; for mRS = 5, HU ranged from -0.33 to 0.15). Patients' mRS scores at 3 months accounted for 65-71% of variation in the generated HU.
We have generated HU stratified by dependency level, using a common trial endpoint, and describing expected variability when applying diverse value sets to an international population. These will improve future cost-effectiveness analyses. However, care should be taken to select appropriate value sets.
健康效用(HU)为特定健康状态赋予偏好权重,是成本效益分析所必需的。现有的中风健康效用未能充分反映中风后残疾的范围。利用国际中风试验数据,我们计算了按残疾分层的健康效用,以提高未来成本效益分析的精度。
我们使用虚拟国际中风试验档案库(VISTA)中的欧洲生活质量评分(EQ-5D-3L)数据来计算健康效用,按3个月时的改良Rankin量表评分(mRS)分层。我们应用已发表的价值集来生成健康效用,并使用普通最小二乘法回归进行验证,同时对年龄和基线美国国立卫生研究院卒中量表(NIHSS)评分进行调整。
我们的分析纳入了3858例急性缺血性中风患者(平均年龄:67.5±12.5,基线NIHSS:12±5)。我们使用来自13个国家的价值集得出健康效用,并观察到健康效用分布存在显著的国际差异(Wilcoxon符号秩检验<0.0001,与英国值相比)。对于mRS = 0,平均健康效用范围为0.88至0.95;对于mRS = 5,平均健康效用范围为 -0.48至0.22。普通最小二乘法回归得出的健康效用相当(对于mRS = 0,健康效用范围为0.9至0.95;对于mRS = 5,健康效用范围为 -0.33至0.15)。患者3个月时的mRS评分占所生成健康效用变异的65 - 71%。
我们使用共同的试验终点,生成了按依赖程度分层的健康效用,并描述了将不同价值集应用于国际人群时预期的变异性。这些将改善未来的成本效益分析。然而,应谨慎选择合适的价值集。